Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells Retraction in /10.3892/or.2021.8144

Yang,Qu; Zhang,Shanyong; Kang,Mingyang; Dong,Rongpeng; Zhao,Jianwu

doi:10.3892/or.2015.3832

Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells

Retraction in: /10.3892/or.2021.8144

Authors:
- Qu Yang
- Shanyong Zhang
- Mingyang Kang
- Rongpeng Dong
- Jianwu Zhao
View Affiliations

Affiliations: Department of Orthopedics, The Second Hospital of Jilin University, Changchun, Jilin 130042, P.R. China
Published online on: March 4, 2015 https://doi.org/10.3892/or.2015.3832
Pages: 2537-2544

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Molecular-targeted therapy has shown promise as a treatment for advanced osteosarcoma (OS). Sorafenib (SOR), a multikinase inhibitor, is the approved systemic drug of choice for OS, but has demonstrated limited benefits due to its toxicity and other adverse effects. Therapy strategies for reducing toxicity include using lower doses of SOR in combination with other complementary agents. Cisplatin (CDDP) has been shown to be a promising anticancer drug against various types of cancer including OS. In the present study, SOR was combined with CDDP to determine whether this combinatorial treatment suppressed tumor growth thereby simultaneously reducing doses of the two drugs for the treatment of OS. Human Saos-2 OS cells were treated with SOR and CDDP, alone and in combination, and the effect of these treatments on cell proliferation, colony formation, cell cycle, apoptosis, migration, and invasion, and involvement in receptor signaling, as well as tumor growth ability in nude mice was determined. It was found that the combination of low concentrations of SOR and CDDP significantly suppressed the cell proliferation, colony formation, migration and invasion, and induced cell apoptosis and cell cycle arrest in the G0/G1 stage, and suppressed tumor growth in a nude mouse model compared to the actions of either agent alone. The results also showed that SOR in combination with CDDP significantly suppressed the phosphorylation of extracellular signal-regulated kinase (ERK), which may contribute to the inhibition of tumor growth. These results suggested that SOR in combination with CDDP acts synergistically in the treatment of OS.

View Figures

View References

1	Ottaviani G, Robert RS, Huh WW, Palla S and Jaffe N: Sociooccupational and physical outcomes more than 20 years after the diagnosis of osteosarcoma in children and adolescents: limb salvage versus amputation. Cancer. 119:3727–3736. 2013.PubMed/NCBI
2	Ottaviani G and Jaffe N: The epidemiology of osteosarcoma. Cancer Treat Res. 152:3–13. 2009. View Article : Google Scholar
3	Ta HT, Dass CR, Choong PF and Dunstan DE: Osteosarcoma treatment: state of the art. Cancer Metastasis Rev. 28:247–263. 2009. View Article : Google Scholar : PubMed/NCBI
4	Chou AJ, Kleinerman ES, Krailo MD, et al: Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer. 115:5339–5348. 2009. View Article : Google Scholar : PubMed/NCBI
5	Grignani G, Palmerini E, Dileo P, et al: A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 23:508–516. 2012. View Article : Google Scholar
6	Wilhelm SM, Carter C, Tang L, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
7	Liu L, Cao Y, Chen C, et al: Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66:11851–11858. 2006. View Article : Google Scholar : PubMed/NCBI
8	Mei J, Zhu X and Wang Z and Wang Z: VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma Mg63 cells with sorafenib treatment. Cell Biochem Biophys. 69:151–156. 2014. View Article : Google Scholar : PubMed/NCBI
9	Almhanna K and Philip PA: Safety and efficacy of sorafenib in the treatment of hepatocellular carcinoma. Onco Targets Ther. 2:261–267. 2009.PubMed/NCBI
10	Strumberg D, Clark JW, Awada A, et al: Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors. Oncologist. 12:426–437. 2007. View Article : Google Scholar : PubMed/NCBI
11	Lacouture ME, Reilly LM, Gerami P and Guitart J: Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 19:1955–1961. 2008. View Article : Google Scholar : PubMed/NCBI
12	Zhang H, Li Z and Wang K: Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo. Oncol Rep. 31:1954–1960. 2014.PubMed/NCBI
13	Morisaki T, Umebayashi M, Kiyota A, et al: Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro. Anticancer Res. 33:1387–1395. 2013.PubMed/NCBI
14	Pignochino Y, Dell’Aglio C, Basirico M, et al: The combination of sorafenib and everolimus abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res. 19:2117–2131. 2013. View Article : Google Scholar : PubMed/NCBI
15	Ma JJ, Chen BL and Xin XY: XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma. Eur J Obstet gynecol Reprod Biol. 146:222–226. 2009. View Article : Google Scholar : PubMed/NCBI
16	Cheng JQ, Jiang X, Fraser M, et al: Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway. Drug Resist Updat. 5:131–146. 2002. View Article : Google Scholar : PubMed/NCBI
17	Holt SV, Brookes KE, Dive C and Makin GW: Downregulation of XIAP by AEG35156 in paediatric tumor cells induces apoptosis and sensitises cells to cytotoxic agents. Oncol Rep. 25:1177–1181. 2011.PubMed/NCBI
18	Tao C, Lin H and Chen S: The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells. Gene. 552:106–115. 2014. View Article : Google Scholar : PubMed/NCBI
19	Yuan JM, Li XD, Liu ZY, et al: Cisplatin induces apoptosis via upregulating Wrap53 in U-2OS osteosarcoma cells. Asian Pac J Cancer Prev. 12:3465–3469. 2011.PubMed/NCBI
20	Abe S, Nishimoto Y, Isu K, Ishii T and Goto T: Japanese Musculoskeletal Oncology Group: Preoperative cisplatin for initial treatment of limb osteosarcoma: its local effect and impact on prognosis. Cancer Chemother Pharmacol. 50:320–324. 2002. View Article : Google Scholar : PubMed/NCBI
21	Anninga JK, Gelderblom H, Fiocco M, et al: Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 47:2431–2445. 2011. View Article : Google Scholar : PubMed/NCBI
22	Zhao JG, Ren KM and Tang J: Overcoming 5-Fu resistance in human non-small cell lung cancer cells by the combination of 5-Fu and cisplatin through the inhibition of glucose metabolism. Tumour Biol. 35:12305–12315. 2014. View Article : Google Scholar : PubMed/NCBI
23	Murakami M, Zhao S, Zhao Y, et al: Increased intratumoral fluorothymidine uptake levels following multikinase inhibitor sorafenib treatment in a human renal cell carcinoma xenograft model. Oncol Lett. 6:667–672. 2013.PubMed/NCBI
24	Gollob JA, Wilhelm S, Carter C and Kelley SL: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 33:392–406. 2006. View Article : Google Scholar : PubMed/NCBI
25	Walter I, Wolfesberger B, Miller I, et al: Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS. Oncol Rep. 31:1147–1156. 2014.PubMed/NCBI
26	Ullah MF: Cancer multidrug resistance (MDR): a major impediment to effective chemotherapy. Asian Pac J Cancer Prev. 9:1–6. 2008.PubMed/NCBI
27	Meyers PA, Schwartz CL, Krailo M, et al: Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 23:2004–2011. 2005. View Article : Google Scholar : PubMed/NCBI
28	Bruheim S, Xi Y, Ju J and Fodstad O: Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide. Clin Cancer Res. 15:7161–7169. 2009. View Article : Google Scholar : PubMed/NCBI
29	Yu WX, Tang LN, Lin F, Yao Y and Shen Z: Comparison of pemetrexed plus cisplatin with gemcitabine plus docetaxel in refractory/metastatic osteosarcoma: clinical outcomes from a retrospective database monitored in a single institute. Oncol Lett. 8:2243–2248. 2014.PubMed/NCBI
30	Lin F, Wang Q, Yu W, et al: Clinical analysis of Chinese limb osteosarcoma patients treated by two combinations of methotrexate, cisplatin, doxorubicin and ifosfamide. Asia Pac J Clin Oncol. 7:270–275. 2011. View Article : Google Scholar : PubMed/NCBI
31	Wei Y, Shen N, Wang Z, et al: Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling. Mol Cell Biochem. 381:139–144. 2013. View Article : Google Scholar : PubMed/NCBI
32	Martinez-Lopez N, Athonvarangkul D, Mishall P, Sahu S and Singh R: Autophagy proteins regulate ERK phosphorylation. Nat Commun. 4:27992013. View Article : Google Scholar : PubMed/NCBI
33	Hayakawa J, Ohmichi M, Kurachi H, et al: Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem. 274:31648–31654. 1999. View Article : Google Scholar : PubMed/NCBI
34	Mandic A, Viktorsson K, Heiden T, Hansson J and Shoshan MC: The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res. 11:11–19. 2001. View Article : Google Scholar : PubMed/NCBI
35	Eicher C, Dewerth A, Thomale J, et al: Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts. Br J Cancer. 108:334–341. 2013. View Article : Google Scholar :
36	Wang X, Martindale JL and Holbrook NJ: Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem. 275:39435–39443. 2000. View Article : Google Scholar : PubMed/NCBI
37	Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK and Cheng AL: Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. Biochem Pharmacol. 63:142–1430. 2002. View Article : Google Scholar
38	Woessmann W, Chen X and Borkhardt A: Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol. 50:397–404. 2002. View Article : Google Scholar : PubMed/NCBI